Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model

Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1−CD8+ Tumor-Infiltrating T Cells

(2019) Sema Kurtulus et al.   IMMUNITY

A CD40 agonist and PD-1 antagonist antibody reprogram the microenvironment of non-immunogenic tumors to allow T cell-mediated anticancer activity

(2019) Hayley S. Ma et al.   Cancer Immunology Research

Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

(2019) Brian C. Miller et al.   NATURE IMMUNOLOGY

Identification of a neo-epitope dominating endogenous CD8 T cell responses to MC-38 colorectal cancer

(2019) Brett J. Hos et al.   OncoImmunology

European cancer mortality predictions for the year 2018 with focus on colorectal cancer

(2018) M Malvezzi et al.   ANNALS OF ONCOLOGY

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Macrophage-derived granulin drives resistance to immune checkpoint inhibition in metastatic pancreatic cancer

(2018) Valeria Quaranta et al.   CANCER RESEARCH

Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors

(2018) Thomas Duhen et al.   Nature Communications

NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines

(2018) Nadine van Montfoort et al.   CELL

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells

(2018) Pascale André et al.   CELL

Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma

(2018) Hanjie Li et al.   CELL

Metabolic and Epigenetic Coordination of T Cell and Macrophage Immunity

(2017) Anthony T. Phan et al.   IMMUNITY

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

(2017) John P Neoptolemos et al.   LANCET

Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer

(2017) Vinod P. Balachandran et al.   NATURE

Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy

(2016) Se Jin Im et al.   NATURE

IFN  and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma

(2016) K. B. Long et al.   Cancer Discovery

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

(2015) A. Patnaik et al.   CLINICAL CANCER RESEARCH

Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6Clow F4/80+ Extratumoral Macrophages

(2015) Gregory L. Beatty et al.   GASTROENTEROLOGY

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

(2015) Jeffrey S Weber et al.   LANCET ONCOLOGY

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center retrospective study

(2015) Ippei Matsumoto et al.   PANCREATOLOGY

T cell metabolic fitness in antitumor immunity

(2015) Peter J. Siska et al.   TRENDS IN IMMUNOLOGY

Characteristics of 10-Year Survivors of Pancreatic Ductal Adenocarcinoma

(2015) Alessandro Paniccia et al.   JAMA Surgery

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

(2014) L. Rahib et al.   CANCER RESEARCH

CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models

(2014) Y. Zhu et al.   CANCER RESEARCH

The Glucose Transporter Glut1 Is Selectively Essential for CD4 T Cell Activation and Effector Function

(2014) Andrew N. Macintyre et al.   Cell Metabolism

Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity

(2014) Ingunn M Stromnes et al.   GUT

CD40 immunotherapy for pancreatic cancer

(2013) Robert H. Vonderheide et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Agonistic CD40 Antibodies and Cancer Therapy

(2013) R. H. Vonderheide et al.   CLINICAL CANCER RESEARCH

Network Analysis Reveals Centrally Connected Genes and Pathways Involved in CD8+ T Cell Exhaustion versus Memory

(2012) Travis A. Doering et al.   IMMUNITY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

(2011) G. L. Beatty et al.   SCIENCE

Pancreatic adenocarcinoma exerts systemic effects on the peripheral blood myeloid and plasmacytoid dendritic cells: an indicator of disease severity?

(2010) Vegard Tjomsland et al.   BMC CANCER

The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

(2009) M. A. Cheever et al.   CLINICAL CANCER RESEARCH

Antigens for cancer immunotherapy

(2008) Michelle A. Neller et al.   SEMINARS IN IMMUNOLOGY